ニュース

PRESS RELEASE

PRISM BioLab and Lilly Enter into a Drug Discovery Collaboration on a

Protein-Protein Interaction Target

•Collaboration focused on discovering oral inhibitors of protein-protein interaction (PPI)

targets by leveraging PRISM BioLab’s proprietary PepMetics® technology.

•PRISM BioLab receives upfront payments and up to $660 million in total milestones, plus

royalties on net sales.

TOKYO, Japan, 28 Nov 2023: -- PRISM BioLab, Co. Ltd. (“PRISM”), a leading discovery and development

biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets,

today announced that it has entered into a License and Collaboration Agreement with Eli Lilly and

Company (“Lilly”).

Under the agreement, PRISM and Lilly will collaborate to discover small molecule inhibitors of a PPI target

selected by Lilly utilizing PRISM’s proprietary PepMetics® technology. Lilly has the option to add up to two

more targets to the collaboration and is responsible for the clinical development and commercialization of

resulting products. PRISM will receive upfront payments and is eligible to receive up to $660 million in preclinical, clinical and commercial development milestones payments, as well as royalties on product sales.

“We are very excited to enter into this collaboration with Lilly as we apply our technology to expand the

field of drug discovery into a novel approach to drug the PPI targets,” said Dai Takehara, President and

Chief Executive Officer of PRISM Biolab. “Our PepMetics® technology holds promise to change the current

paradigm in drug discovery by turning previously undruggable PPIs into targets readily druggable with small

molecules. This collaboration with Lilly, an innovative global pharma company, could help us realize this

vision and expand the field of druggable targets for the benefit of patients.”

About PRISM BioLab

PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics®

technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets

and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics®

are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn,

the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By

combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics®

technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the

field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small

molecules and by generating oral small molecule alternatives for injectable biologics.

PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies.

PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai and Ohara Pharmaceuticals are in clinical

development for cancer and liver disease, respectively.

www.prismbiolab.com

PRISM BioLab、米国製薬大手イーライリリー・アンド・カンパニーと
ライセンスおよび共同研究契約を締結
株式会社 PRISM BioLab（代表取締役 竹原 大 本社：神奈川県、以下「PRISM」）
は、Eli Lilly and Company（CEO：David A. Ricks 本社：米国、インディアナ州、
以下「Lilly」）との間で創薬に関するライセンスおよび共同研究契約を締結しま
した。
今回の契約締結により両社は、タンパク質／タンパク質相互作用（PPI）を標的
とした PRISM 独自の低分子によるペプチド模倣技術『PepMetics® 技術』を用いて、
Lilly の創薬ターゲットに対する開発候補化合物を共同開発します。Lilly は、二
つの創薬標的を追加するオプションを持ち、臨床開発ならびに商業化する権利を得
ます。
これにより、PRISM は契約一時金及び前臨床・臨床・販売に応じて総額で最大 6
億 6,000 万ドルのマイルストンと、売上に応じたロイヤリティを受取る権利を得ま
す。
■PRISM BioLab 代表取締役社長 竹原 大 コメント
PPI を標的とする新たな創薬アプローチである当社独自のペプチド模倣技術
『PepMetics® 技術』を用いて、Lilly との共同研究を開始できることを非常に嬉
しく思います。『PepMetics® 技術』は、これまで創薬不可能な標的とされてきた
PPI を、低分子を用いて容易に制御可能とすることにより、あらたな創薬のパラダ
イムを創造する可能性を秘めています。革新的なグローバル製薬企業である Lilly
との協業を通じて私たちのビジョンを実現し、患者さんに新たな治療薬を提供でき
ることをチーム一同楽しみにしています。